Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Kalmar "Growth-with-Value" Small Cap Fund Investor Class (KGSCX)

Net Asset Value
1 Day
Overall Morningstar Rating
Small growth
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. Under normal market conditions, the fund will invest at least 80% of its assets in the common stocks of small capitalization ("small cap") companies. The fund's managers consider small cap companies to be companies whose stock market capitalizations (total equity market value of outstanding shares) are $3.5 billion or less at the time of purchase or companies whose stock market capitalizations are within the current market capitalization range of the Russell 2000 Growth Index or the Russell 2000 Index at the time of purchase.


1 month+3.61% 3 years+1.22%
3 months+5.52% 5 years+7.49%
1 year+30.42% Since inception+8.34%
Data through --

Peer Comparisonvs. Small growth

Performance 5-yr return+7.49%+12.33%
Expense ratio1.36%1.32%
Risk 5 year sharpe ratio0.600.82
Net assets$128.5M$877.7M
Average market cap$2.1B$3.2B
Average P/E32.929.4
Portfolio turnover50%50%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyKalmar Investments
Fund manager & tenureFord Draper / 19 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00


U.S. stock113.24%
International stock2.18%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Industrial materials 15.33%
Consumer service 14.02%
Healthcare 11.58%
Business service 10.59%
Hardware 9.21%
Top 10 Holdings
Portfolio weighting
WST West Pharmaceutical Services Inc4.33%
ACXM Acxiom Corp3.34%
GTT GTT Communications Inc3.00%
PDCE PDC Energy Inc2.77%
MXL MaxLinear Inc2.75%
WAGE WageWorks Inc2.72%
MTDR Matador Resources Co2.62%
TXRH Texas Roadhouse Inc2.59%
RGEN Repligen Corp2.57%
LGND Ligand Pharmaceuticals Inc2.52%